Wall Street Zen upgraded shares of Apnimed (NASDAQ:APMD – Free Report) to a hold rating in a research note issued to investors on Saturday morning.
Apnimed Stock Performance
Shares of APMD stock opened at $27.94 on Friday. Apnimed has a twelve month low of $16.12 and a twelve month high of $29.76.
Insiders Place Their Bets
In other news, major shareholder Morningside Venture Investment purchased 312,500 shares of the stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the insider owned 7,152,713 shares of the company’s stock, valued at $114,443,408. The trade was a 4.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
About Apnimed
Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.
Recommended Stories
- Five stocks we like better than Apnimed
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
